Background: The identification of combinatorial antibodies against many
different targets in oncology, autoimmune, inflammatory and infectious diseases has
uncovered novel strategies to control and prevent diseases’ onset and progression, and
represents the fastest growing market for the pharmaceutical industry. Phage Display has
been successfully used in the identification of unknown targets, which combines shotgun
approaches with high throughput selection schemes.
Methods: This specific review covers many aspects of combinatorial phage display
technology starting from antibody selection strategies to its redesign for application
purposes. Emphasis is specifically directed to how these biotherapeutics function on specific
targets with an interactome view, especially within complex diseases.
Conclusion: Novel combinatorial antibodies will lead to improved interventions in cancer,
autoimmune and infectious diseases; however, the very large genetic diversity associated with environmental
variations highlight the importance of the personalized medicine using a system’s biology approach. Therefore,
combined therapies are expected in the near future.